To recover your password please fill in your email address
Please fill in below form to create an account with us
Medulloblastoma is the most common malignant brain tumour of childhood but can also occur in older adolescents and young adults. The optimal management of these older patients is unknown, and till now their treatment has been suboptimal. PersoMed-I will give these patients access to state of the art tumour profiling and targeted therapies in order to ensure optimal treatments, reduce toxicities and improve cure rates.
|
Trial Summary |
PersoMed-I is a phase II, randomised international trial that represents a collaboration between the EORTC and COGNO. The study is investigating if personalized risk-adapted therapy improves outcomes and reduces toxicity in post-pubertal patients with newly diagnosed medulloblastoma. The PersoMed-I study aims to recruit 205 patients across Europe and Australia, which includes 33 participants Australia-wide. |
|
Supported by |
This project is funded by CanTeen Australia’s Australian Young Cancer Patient Clinical Trials Initiative, which is supported by the Commonwealth Department of Health via the Medical Research Future Fund. This project is also supported by grant 1165910 awarded through the 2018 Priority-driven Collaborative Cancer Research Scheme and co-funded by Cancer Australia and The Kids’ Cancer Project. |
|
Eligibility |
Post-pubertal and adults with newly diagnosed medulloblastoma (WNT M0-1, SHH M0-1 (p53wt), Group 3 & Group 4 M0-1) |
|
Registration ID |
NCT04402073 |
|
Participation (countries) |
Europe, Australia |
|
Australian lead group |
COGNO |
|
Status |
Recruiting |
|
Activation date |
12th July 2023 |
|
Co-Chairs |
Prof David Ziegler & Associate Prof Elizabeth Hovey |
|
Contact |